Breast cancer is not a single disease but a biologically heterogeneous group of malignancies arising from breast epithelium. Clinical practice increasingly relies on molecularly guided classification, particularly three major immunohistochemical or receptor-defined subtypes: hormone receptor–positive (HR+, typically estrogen receptor [ER] and/or progesterone receptor [PR]), HER2-positive (HER2+), and triple-negative breast cancer (TNBC), defined by lack of ER and PR and absence of HER2 overexpression/amplification. These categories have direct implications for tumor growth pathways, metastatic risk, sensitivity to systemic therapies, and the design of rational treatment sequences.
HR-positive breast cancer is driven largely by signaling through nuclear hormone receptors. When ER and/or PR are expressed, tumor cells often depend on estrogen-mediated transcriptional programs that promote proliferation, survival, and invasion. Standard management uses endocrine therapy to interrupt this pathway. Therapeutic strategies include selective estrogen receptor degraders/modulators (for example, tamoxifen historically and fulvestrant for ER degradation) and aromatase inhibitors in postmenopausal patients, which reduce peripheral estrogen synthesis. In premenopausal patients, ovarian suppression via luteinizing hormone–releasing hormone agonists can be used to decrease circulating estrogen. Clinically, HR+ disease generally has a more favorable baseline prognosis than TNBC, but late recurrences can occur; thus, extended endocrine therapy is often considered. Resistance mechanisms may involve altered receptor signaling, ligand-independent activation, and downstream pathway crosstalk (e.g., PI3K/AKT/mTOR). This has expanded the role of targeted combinations, including CDK4/6 inhibitors and selective PI3K pathway agents in appropriate patients.
HER2-positive breast cancer is characterized by amplification or overexpression of the ERBB2 gene, leading to ligand-independent activation of receptor tyrosine kinase signaling. This cascade activates proliferative and anti-apoptotic pathways (commonly MAPK and PI3K/AKT). Because the driver is a surface receptor, HER2-targeted monoclonal antibodies and antibody–drug conjugates form the therapeutic backbone. Trastuzumab, for example, blocks HER2 signaling and recruits immune effector functions; it has been shown to improve outcomes across multiple disease settings. Pertuzumab targets a distinct HER2 dimerization site, providing dual HER2 blockade. More advanced regimens may incorporate antibody–drug conjugates that deliver cytotoxic payloads directly to HER2-expressing cells, and small-molecule tyrosine kinase inhibitors in selected circumstances. Despite effectiveness, HER2+ tumors can develop resistance through changes in signaling circuitry, receptor shedding, or compensatory activation of alternative growth receptors.
Triple-negative breast cancer represents the receptor profile lacking ER, PR, and HER2, which removes the benefits of established receptor-targeted endocrine and HER2 therapies. TNBC is therefore more frequently managed with cytotoxic chemotherapy—such as taxanes, anthracyclines, and DNA-damaging agents depending on staging and prior treatment. However, TNBC is biologically diverse. Some tumors show basal-like features, enrichment of immune signaling, or defects in DNA repair pathways. These differences influence response to therapy. Immune checkpoint inhibition has become relevant for subsets with higher immune activity, including tumors with tumor-infiltrating lymphocytes or biomarkers such as PD-L1 expression, particularly in the early-stage high-risk setting when combined with chemotherapy. Additionally, TNBC associated with germline or somatic homologous recombination deficiency may be treated with PARP inhibitors, which exploit impaired DNA repair to enhance tumor cell death.
Across subtypes, treatment selection integrates stage, patient comorbidities, prior therapy, and measurable biomarkers. For clinicians, receptor status is determined by pathology using validated assays, including ER/PR immunohistochemistry and HER2 testing with reflex methods (immunohistochemistry and in situ hybridization when necessary). Beyond receptors, contemporary care increasingly uses genomic profiling to refine risk estimates, guide clinical trial eligibility, and identify actionable alterations.
Prognosis varies by subtype and stage. HR+ disease can recur years after diagnosis, requiring long-term surveillance strategies and adherence to endocrine therapy. HER2+ disease historically had poorer outcomes but improved substantially with HER2-targeted regimens, which have shifted survival curves. TNBC remains challenging due to limited targeted options and higher rates of early recurrence, though emerging biologic stratification is steadily improving treatment precision.
In practice, multidisciplinary management is essential: surgeons, medical oncologists, radiation oncologists, pathologists, and genetic counselors collaborate to ensure appropriate staging, biomarker testing, systemic therapy sequencing, and supportive care. For patients, counseling should address the rationale behind subtype-specific therapy, the expected timing of benefit, and potential toxicities. For clinicians, ongoing trials and evolving biomarkers underscore the necessity of staying current with evidence-based guidelines.
Source: Medscape
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
